← Browse by Condition
Medical Condition

nsclc stage iv

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for nsclc stage iv sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nsclc stage iv Clinical Trials

How many clinical trials are currently recruiting for nsclc stage iv?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for nsclc stage iv, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for nsclc stage iv?
nsclc stage iv research spans Phase 1 (2 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a nsclc stage iv clinical trial?
Eligibility criteria for nsclc stage iv trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
4
Phase 3
1
Top Sponsors
Jinzhou Medical University 1 trial
Tianjin Medical University Cancer Institute and Hospital 1 trial
Jun Zhang, MD, PhD 1 trial
ImmunityBio, Inc. 1 trial
Arbeitsgemeinschaft medikamentoese Tumortherapie 1 trial

Recruiting Clinical Trials

NCT06512207
Recruiting
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Enrollment
80 pts
Location
China
Sponsor
Jinzhou Medical University
View Trial →
NCT07548060 Phase 2
Recruiting
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Enrollment
25 pts
Location
China
Sponsor
Tianjin Medical University Can...
View Trial →
NCT05332925
Recruiting
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Enrollment
25 pts
Location
United States
Sponsor
Jun Zhang, MD, PhD
View Trial →
NCT06745908 Phase 3
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Enrollment
507 pts
Location
United States, Canad...
Sponsor
ImmunityBio, Inc.
View Trial →
NCT04654364
Recruiting
Lung Cancer Registry
Enrollment
500 pts
Location
Austria
Sponsor
Arbeitsgemeinschaft medikament...
View Trial →
NCT04467723 Phase 1, Phase 2
Recruiting
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Enrollment
25 pts
Location
United States
Sponsor
University of Kansas Medical C...
View Trial →
NCT05950139 Phase 1, Phase 2
Recruiting
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Enrollment
12 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca...
View Trial →
NCT05344209 Phase 2
Recruiting
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
Enrollment
138 pts
Location
Norway
Sponsor
Vestre Viken Hospital Trust
View Trial →

Related Conditions

nsclc stage iii (3) lung cancer (2) egfr gene mutation (1) nsclc (1) sclc extensive stage (1) sclc limited stage (1) nsclc recurrent (1) alk fusion protein expression (1) oncology (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology